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Abstract
Dystrophic epidermolysis bullosa (DEB) is a hereditary skin fragility disorder, characterized by trauma-induced
blistering followed by soft tissue fibrosis. One of the most feared complications is the early development of
aggressive cutaneous squamous cell carcinomas (SCC). For patients with locally advanced or metastasized SCCs
treatment with cetuximab, a monoclonal antibody against epidermal growth factor receptor (EGFR), has been
proposed and so far, treatment of five DEB patients with cetuximab has been published. With this report, we
extend the spectrum of EB patients treated with cetuximab by adding two additional patients. Taking together all
DEB cases treated with cetuximab, we propose that cetuximab should be administered as early as possible, since it
seems to be more efficient and is accompanied by rather mild adverse effects. We also show that EGFR is
frequently expressed in DEB-associated SCCs, although there were noticeable differences in the level of expression,
which may influence responsiveness to EGFR-targeting therapies. Although only limited experiences with targeted
cancer treatments in EB exist, such reports highlight the treatments’ effects in this specific cohort and assist our
therapeutic decisions.
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Dystrophic epidermolysis bullosa (DEB) is a hereditary
skin fragility disorder, characterized by trauma-induced
blistering followed by soft tissue fibrosis [1]. One of the
most feared complications is the development of aggres-
sive cutaneous squamous cell carcinomas (SCCs) [2, 3].
Patients suffering from the most severe generalized re-
cessive DEB subtype (RDEB-gen sev) have the highest
risk (rising up to 90.1% by the age of 55) [4]. Metastatic
SCCs also represent the most common cause of death in
adults with RDEB [4]. Moreover, although SCCs are usu-
ally well differentiated, they tend to relapse [5]. The
standard treatment of EB-associated SCC is wide local
excision. In some cases amputation is necessary [6].
Treatment with cetuximab, a monoclonal antibody
against epidermal growth factor receptor (EGFR), has
been proposed for patients with advanced or metasta-
sized SCCs [6, 7]. Although not every determinant of
cetuximab response or resistance has been identified,
this treatment is associated with better responses, if
EGFR is expressed in the tumor [8]. Besides the fact that
no comprehensive studies on the expression of EGFR in
EB-related SCCs have been published so far, EB patients
with metastasized cutaneous SCCs treated with cetuxi-
mab are reported in the literature [8–10].
Here, we stained 10 RDEB-gen sev-associated SCCs of
different differentiation grades for EGFR expression. The
goal was to determine the percentage of patients, eligible
for cetuximab treatment. In all EGFR stained positive,
although there was considerable heterogeneity in the
staining intensity (Fig. 1). Subsequently, we treated two
patients with RDEB-gen sev with SCCs with cetuximab.
Patient 1. A 49-year-old female with RDEB-gen sev
with a history of multiple and multifocal cutaneous
SCCs, predominately on the extremities, presented with
a new large poorly differentiated SCC at the right lower
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leg (Fig. 2a). Wide local excision had initially been per-
formed with histologically-proven clear peripheral and
deep margins. Within 1 month after surgery the tumor
recurred and grew rapidly. In addition, axillary and para-
iliacal lymph node metastases were detected by magnetic
resonance imaging (MRI) and positron emission tomog-
raphy / computed tomography (PET/CT-scan) with 18F-
Fluoro-2-deoxy-2-D-glucose (FDG), which showed
pathologically increased glucose metabolism (Fig. 2b).
The patient refused lymph node dissection due to her
severe skin condition and delayed wound healing. As the
immunohistochemistry of the primary tumor from the
right lower leg was positive for EGFR (Fig. 2c), the patient
received cetuximab with a loading dose of 400mg/m2 and
afterwards 250mg/m2 weekly for about 6months. Around
5 months after cetuximab initiation, the parailiacal lymph
node metastasis had almost disappeared and the axillary
metastasis showed only minimal residual glucose hyper-
metabolism (Fig. 2b). During the treatment the patient ex-
perienced no adverse effects, beside slower wound
healing. Unfortunately, the mass on the right lower leg did
not regress. Six months after initiation of cetuximab ther-
apy a haemodynamically-relevant bleeding of the tumor
led to amputation of the right lower leg. Thereafter, the
patient refused any further treatment or diagnostic
procedures. Despite the fact that no more excisions,
systemic treatments or radiotherapy were performed, the
patient survived for 40months after cetuximab discon-
tinuation. This time period was longer than predicted on
the basis of our experience and the data reported in litera-
ture with metastatic SCCs [3, 4].
Patient 2. A 15-year-old girl with RDEB-gen sev pre-
sented with a large (> 15 cm) ulcerated skin tumor on
the left deltoid (Fig. 3). She was in a poor general condi-
tion, displaying the characteristic RDEB-gen sev related
clinical features. Histology confirmed a well differenti-
ated SCC positive for EGFR (Fig. 3f). CT scan revealed
left axillary lymph nodes metastases. The deltoid SCC
displayed initial regression after electrochemotherapy,
but 1 month later it rapidly progressed with the onset of
new nodular lesions on the sternum and enlargement of
the primary tumor (Fig. 3a, c). A new total-body CT
scan revealed multiple, new left clavicular and bilateral
axillary lymph node metastases. Based on immunohisto-
chemical analysis (Fig. 3f), cetuximab was administered
with a weekly dosage of 250 mg/m2. After 3 months, the
patient revealed reduced pain, the primary tumor
(Fig. 3b) and the lesion on the back were flattened,
while the sternal nodule continued to grow (Fig. 3d).
After 24 weeks of treatment, the disease progressed
Fig. 1 EGFR staining of 10 RDEB-related SCCs is positive in all tumors, although there is a notable variability among different tumors. a Ten
primary RDEB-related cSCCs stained for EGFR and keratin 14. RDEB cSCCs are generally well differentiated and maintain keratin 14 expression [11].
b Quantification of the mean EGFR staining in tumor sections after normalization to keratin 14 staining in adjacent sections. The data are
expressed as percentage of EGFR / keratin 14 ratio in control skin
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with development of new nodules, increase of the
previous lesions and pelvic pain. At this point, cetuxi-
mab was discontinued.
With this report we extend the spectrum of EB pa-
tients treated with cetuximab, which is used in locally-
advanced and metastasized head and neck SCCs [12]. In
three previously published cases of EB [6, 8], cetuximab
was administered sequentially after radio- and chemo-
therapy in order to reduce potential skin toxicity,
bearing in mind that treated patients often develop
papulopustular or acneiform rashes, xerosis, as well as
alterations of hair and nail beds [13]. The already pub-
lished EB patients died within a few months after cetuxi-
mab initiation (Table 1 and personal communication
with Dr. Arnold in Basel, Switzerland). In another re-
cently published case [10], cetuximab was given as a
first-line treatment after diagnosis of lymph node metas-
tasized SCC, with a progression-free survival of 9
months and a survival after treatment of at least 2 years.
The treatment was well-tolerated, besides wound healing
impairment. Our patient 1 showed a similarly long
progression-free survival as in the aforementioned report
and comparable adverse effects.
In our 2 patients with cutaneous SCCs and lymph
node metastases, cetuximab was initially used as the
sole treatment. Contrasting previous reports [8, 9],
patient 1 survived for around 4 years after cetuximab
initiation, while patient 2, who had a more advanced
disease and poor general condition, survived only 4.5
months. In addition, pain improved in patient 2
during cetuximab treatment, allowing a better quality
of life in absence of drug side effects. The different
responses of the lymph node metastases versus the
primary tumor, as shown in patient 1, might indicate
intra-tumoral heterogeneity regarding the expression
of EGFR and / or influences of the microenvironment
Fig. 2 a Patient 1 presented with a cauliflower-like tumor at the right lower leg. The tumor did not regress after 4 cycles of cetuximab. b
MRI and 18F-FGD-PET/CT at baseline showed hypermetabolic enlarged node metastases (white and black arrows, respectively) in the left
axilla and pelvis (upper panel). Five months after cetuximab initiation a decrease of the axillary lymph node metastasis in size and
metabolism was observed, while only a faint residuum was noticeable in the pelvic region (lower panel). Also note the increased bone
marrow activity due to concomitant inflammatory reactions associated with the chronic wounds in EB. c IHC of the primary tumor of
patient 1 revealed positive EGFR staining (red)
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on immunotherapy. Based on the overall survival,
patient 1 had a better response to cetuximab than
patient 2. This might at least partially be attributed to
the higher EGFR / keratin 14 ratio in patient 1, as
shown in Fig. 1.
We show that RDEB-gen sev–associated SCCs fre-
quently express EGFR, although there were noticeable dif-
ferences in the level of expression, which may influence
responsiveness to EGFR-targeting therapies [14]. Together
with the absence of major side effects as published so far,
cetuximab could be indicated for this patient population
with inoperable SCCs. Indeed, cetuximab mediates
antibody-dependent cell-mediated cytotoxicity in the
tumor and promotes cellular immunity. In order to coun-
teract regulatory immunosuppressive feedback, it has been
recently suggested to combine immune checkpoint inhibi-
tors with cetuximab, to promote the adaptive and innate
immunity against the tumor [15]. Recently, rigosertib has
also been proposed from nonclinical studies as a thera-
peutic option for late stage, metastatic or unresectable
RDEB SCCs. This molecule inhibits multiple signaling
pathways with a similar profile to PLK1 and induces apop-
tosis in RDEB SCC keratinocytes [16].
Based on our experience, we hypothesize that cetux-
imab may be more efficient for metastasized RDEB-
gen sev–associated SCCs, when administered early. In
fact, reports published so far also suggest that efficacy
might be higher if early administered, giving the pa-
tient a better chance of survival. Cetuximab could
also improve quality of life in patients who cannot
undergo other specific therapies. More studies should
definitely be performed to confirm this hypothesis.
Since only limited experiences with targeted cancer
treatments in EB exist, such reports highlight the
treatments’ effects in this specific patient cohort and
assist our therapeutic decisions.
Fig. 3 a SCC of the left deltoid region. b The same lesion flattened after 12 cycles of cetuximab. c Sternal nodular lesion of the SCC at initial
presentation. d Increasing in size of the same lesion after 12 cycles of cetuximab. e Progression of the disease with onset of multiple new lesions
of the dorsum. f IHC of the primary tumor of patient 2 revealed positive EGFR staining (brown)
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